Item

A Response to the Letter to the Editor: 'Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups'

Krebs, M. G.
; 
Cho, B. C.
; 
Kim, P.
; 
Spira, A. I.
; 
Leighl, N. B.
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Authors
Krebs, M. G.
Cho, B. C.
Kim, P.
Spira, A. I.
Leighl, N. B.
Affiliation
Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom. Electronic address: matthew.krebs@nhs.net. Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea. Johnson & Johnson, Spring House, Pennsylvania. Virginia Cancer Specialists, Fairfax, Virginia. Princess Margaret Cancer Centre, Toronto, Canada.
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Krebs MG, Cho BC, Kim P, Spira AI, Leighl NB. A Response to the Letter to the Editor: "Durable Benefit Beyond Response: Reinterpreting Amivantamab Efficacy in METex14 NSCLC Subgroups". Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025 Oct;20(10):e109-e10. PubMed PMID: 41047189. Epub 2025/10/06. eng.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627457
Embedded videos